• FXR-KLF11 Axis: CDCA Mitigates CI-AKI via JAK2/STAT3 Suppres

  2026-05-12

  This study reveals that Chenodeoxycholic Acid (CDCA), by activating the FXR-KLF11 axis, suppresses the JAK2/STAT3 pathway and affords protection against contrast-induced acute kidney injury (CI-AKI) in preclinical models. The findings establish a mechanistic framework for using FXR agonists in renal protection and point toward translational opportunities in metabolic and renal research.

• Dovitinib (TKI-258): Optimizing Multitargeted RTK Inhibition

  2026-05-12

  Dovitinib (TKI-258, CHIR-258) stands out as a multitargeted RTK inhibitor, enabling precise disruption of cancer signaling pathways and robust apoptosis induction across diverse models. This guide translates complex mechanisms and the latest workflow innovations into actionable protocols, with troubleshooting tips and insights from emerging research, including chamber-specific stem cell applications.

• PTEN mRNA Re-Engineering: Strategy for Resilient Cancer Mode

  2026-05-11

  This thought-leadership article explores how advanced in vitro transcribed mRNA technologies, exemplified by EZ Cap™ Human PTEN mRNA (ψUTP), are redefining the experimental and translational toolkit for overcoming therapeutic resistance in cancer. We dissect the mechanistic underpinnings of PTEN restoration, the strategic design of mRNA constructs, and the translational breakthroughs enabled by immune-evasive, stability-enhanced mRNA platforms in oncology research.

• Prochlorperazine for AMS Prevention: Study Protocol Insights

  2026-05-11

  Small et al. present a rigorously designed randomized controlled trial protocol evaluating prochlorperazine maleate versus placebo for the prevention of acute mountain sickness (AMS) during rapid high-altitude ascent. This study innovatively leverages the mechanistic overlap between AMS and migraine, proposing a repurposed pharmacologic approach with significant implications for travel medicine and high-altitude research.

• Ibuprofen as an Environmental Contaminant: Toxicology and Re

  2026-05-10

  Jan-Roblero and Cruz-Maya's review highlights the environmental persistence and toxicological risks of ibuprofen, an NSAID with high global consumption. The paper underscores the urgent need for effective biodegradation strategies due to limited removal in current wastewater treatments.

• Hexa His Tag Peptide: Optimizing 6X His Protein Purification

  2026-05-09

  The Hexa His tag peptide streamlines the immunoprecipitation of His-tagged proteins, enabling antibody-free elution with high specificity and solubility. This article dissects experimental protocols, troubleshooting, and comparative advantages for robust, reproducible protein purification in advanced research workflows.

• CDK4/6 and BET Inhibitors Synergize Against PDAC via GSK3β–W

  2026-05-08

  Gu et al. reveal that combining CDK4/6 and BET inhibitors robustly suppresses pancreatic ductal adenocarcinoma (PDAC) growth and epithelial-to-mesenchymal transition (EMT) by modulating the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight suggests a rationale for dual-targeted interventions in aggressive pancreatic cancer subtypes.

• SD 169 (indole-5-carboxamide): Precision p38 MAPK Inhibition

  2026-05-08

  Explore how SD 169 (indole-5-carboxamide) uniquely modulates p38 MAPK signaling through conformational control, offering advanced specificity for diabetes and neuroregeneration research. This article reveals new mechanistic and methodological insights beyond standard inhibition.

• PINK1/Park2 Mitophagy Pathway Alleviates NAFLD Progression

  2026-05-07

  This study demonstrates that modulating the PINK1/Park2-mediated mitophagy pathway can alleviate mitochondrial dysfunction and lipid accumulation in non-alcoholic fatty liver disease (NAFLD) models. The findings highlight mitophagy as a promising therapeutic target for NAFLD and provide mechanistic insights into mitochondrial quality control in hepatic pathology.

• iRhom2 Modulates Olfactory Receptor Regulation and Adaptatio

  2026-05-07

  The study by Azzopardi et al. uncovers a novel role for iRhom2 in olfactory sensory neurons, revealing its involvement in odorant receptor repertoire regulation and activity-dependent adaptation. These findings provide a mechanistic basis for negative feedback in olfactory gene expression, with implications for future research in sensory neurobiology.

• CK2 and ERK8 Inhibitor: Mechanism, Evidence, and Protocols

  2026-05-06

  The CK2 and ERK8 inhibitor (2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid) is a high-purity small molecule inhibitor for kinase research. It targets CK2 and ERK8, enzymes central to cell signaling, and is recommended as a molecular tool for enzyme interaction studies. This dossier provides mechanism, evidence, and integration guidance for its application.

• FCCP in Mitochondrial Biology: Protocols & HIF Pathway Insig

  2026-05-06

  APExBIO’s FCCP empowers researchers to dissect mitochondrial function, probe hypoxia-inducible factor (HIF) pathways, and model immunometabolic reprogramming. This guide translates the latest reference findings into actionable workflows, advanced applications, and troubleshooting strategies for optimal use of FCCP in metabolic regulation and cancer research.

• Indomethacin Sodium Trihydrate: Pathway Modulation Beyond CO

  2026-05-05

  Explore how Indomethacin Sodium Trihydrate, a key COX inhibitor, also modulates Wnt/β-catenin and GSK3β pathways for advanced inflammation and regeneration assays. Unique to this article: a deep dive into pathway crosstalk and practical protocol guidance.

• Lipid Nanoparticle Delivery of 2'3'-cGAMP Suppresses Pancrea

  2026-05-05

  Shaji et al. (2024) demonstrate that encapsulating 2'3'-cGAMP in lipid nanoparticles markedly enhances its cytosolic delivery and antitumor efficacy in pancreatic cancer models. This approach addresses key challenges in STING pathway activation, offering a translational strategy for immunotherapy research in immunologically 'cold' tumors.

• VX-661 (F508del CFTR Corrector): Precision Rescue and Varian

  2026-05-04

  Explore the role of VX-661 as a F508del CFTR corrector in cystic fibrosis research. This article uniquely deciphers variant-specific rescue mechanisms and assay design insights, leveraging new calnexin-dependent findings for advanced experimental strategies.

15052 records 1/1004 page Next 12345 下5页 Last page